Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Some birth control pills increase blood clot risk; use them for specific conditions only.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Mutants of CYP154C2 enzyme significantly improved steroid conversion efficiency.

Doxycycline can effectively treat hair loss caused by EGFR inhibitors.

Cubosomal gels enhance skin absorption of cetirizine better than niosomal gels.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Finasteride increases CD8+ T cells in BPH tissues.

Cyproterone and finasteride reduced hypersexuality but caused serious side effects.

Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.

Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Inclisiran is effective at lowering cholesterol.

Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.